Kanai et al. [1] report on the pharmacokinetic properties in healthy human volunteers of theracurmin, a novel nanoparticular formulation of the diet-derived putative cancer chemopreventive agent curcumin. The plasma concentrations reported in this paper are of curcumin conjugates, not of parent curcumin, because the authors routinely hydrolysed plasma samples prior to HPLC analysis using beta-glucuronidase. More than 90 % of curcumin derived-species in the mammalian biophase are curcumin conjugates, predominantly glucuronides. Curcumin also undergoes metabolic reduction. Based on current evidence, parent curcuminrather than its metabolites-is thought to mediate the anticarcinogenic properties of this agent. Therefore, the claim made in this paper that theracurmin achieves ''…improved bioavailability in human subjects…'' as compared to that observed after unformulated curcumin is unsubstantiated. In Table 2 
